Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Focusrite sales soar; Gaming Realms in Slingo boost

Tue, 27th Apr 2021 11:32

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Focusrite PLC - High Wycombe, Buckinghamshire-based music and audio products - Revenue in six months ended February 28 jumps 91% year-on-year to GBP95.3 million from GBP49.9 million. Pretax profit surges to GBP23.6 million from GBP2.7 million a year earlier. "For the first half of the financial year, Focusrite, Novation and ADAM Audio products continued to see high demand for home-based amateur and professional audio recording solutions. This resulted in revenue for the period being slightly ahead of our revised expectations," Chief Executive Officer Tim Carroll says. Ups interim payout to 1.5 pence per share from 1.3p. Also says it has acquired California-based Sequential LLC for USD24 million. Focusrite pays an initial USD20 million to buy the synthesizer company and notes remaining USD4 million is subject to performance-related conditions.

----------

Gaming Realms PLC - London-based mobile games developer - Revenue in 2020 rises 66% to GBP11.4 million from GBP6.9 million. Pretax loss narrows to GBP1.6 million from GBP4.7 million. Gaming Realms notes it "launched with 26 new partners for Slingo Originals content, including 888casino.com, DraftKings, Paddy Power Betfair and Sky Betting & Gaming". Says first-quarter licensing revenue up 60% annually to GBP2.1 million. Adds: "The company expects to be granted a supplier licence in Pennsylvania and launch in the first half of the year. With 9 new partners secured to date in 2021, together with the recent launch of Slingo Starburst in collaboration with NetEnt, the board has every confidence in the strategy being pursued and in the group's prospects for the year ahead. The company is trading marginally ahead of board expectations."

----------

Property Franchise Group PLC - UK-based lettings and estate agency franchising firm - Says revenue in 2020 rises 1.0% to GBP11.5 million from GBP11.4 million. Pretax profit climbs 20% to GBP4.8 million from GBP4.0 million. Dividend rises to 8.7p per share from 2.6p in 2019, though Property Franchise notes it did not pay a final dividend for 2019, before reinstating payouts in 2020. "Trading in the current year has begun well. The primary areas of growth and focus for us in the year ahead will be the increase in franchisees, residential sales activity, portfolio acquisitions, growing our financial services' revenues, improving our digital support channels and integrating Hunters into the group," Property Franchise says. Also notes it has signed five-year pact with LSL Property Services PLC. Deal will see LSL offer "mortgage and protection advice services" to all Property Franchise franchisees. LSL adds: "This agreement underlines the opportunity for further growth of its Financial Services businesses, leveraging LSL's existing leading positions in the mortgage advice market. This contract will enhance the Financial Services division profit after an initial 12-18 month investment period requiring one-off transition and integration costs.

----------

Anexo Group PLC - Liverpool-based legal services provider - Revenue in 2020 rises 11% to GBP86.8 million from GBP78.5 million. Pretax profit falls 31% to GBP15.5 million from GBP22.4 million. Administrative expenses before share based payments were 37% higher at GBP42.6 million from GBP31.0 million. "Both our business divisions have remained fully operational throughout the 2020 and into 2021 and the group has demonstrated considerable resilience. Ongoing investment into our advocacy practice is forming a solid foundation for our strategy of building this into a major contributor to future revenues," Executive Chair Alan Sellers said.

----------

REA Holdings PLC - oil palms in East Kalimantan, Indonesia - Revenue in 2020 rises 11% to USD139.1 million from USD125.0 million in 2019. Pretax loss narrows to USD23.3 million from USD43.7 million. "2020 was a year of two halves. While operationally, satisfactory crop yields were achieved, the sharp fall in the market prices of [crude palm oil] and [crude palm kernel oil] immediately following the onset of the Covid-19 pandemic had a significant negative impact on results for the first half. As prices steadily recovered through the second half, there was a corresponding improvement in financial performance," REA says. "CPO prices are expected to remain firm at or around current levels with growth in global demand for vegetable oils outstripping the growth in supply." Also notes that financing options, including equity raise, being mulled to "strengthen the balance sheet".

----------

Falcon Oil & Gas Ltd - oil and gas explorer focused on Australia, South Africa and Hungary - Revenue in 2020 unchanged at nominal USD5,000. Pretax loss widens to USD1.8 million from USD1.7 million. Loss widens as fair-value gain on outstanding warrant reduces to USD110,000 from USD369,000.

----------

Rambler Metals & Mining PLC - Ming copper-gold mine in Newfoundland & Labrador, Canada - Revenue in 2020 falls 34% to USD24.3 million from USD37.1 million in 2019. Pretax loss narrows to USD11.8 million from USD13.5 million. Reports USD593,000 gain in fair value of forward contract, compared to USD1.3 million loss in 2019. Gold output falls 42% to 2,819 ounces, copper production down 29% to 3,769 tonnes.

----------

Egdon Resources PLC - UK-focused oil & gas exploration and production - Revenue in six months ended January 31 falls 37% to GBP424,000 from GBP675,000 a year earlier. Pretax loss narrows to GBP1.0 million from GBP3.2 million. Total cost of sales trimmed down to GBP998,000 from GBP3.3 million. Output during period was 92 barrels of oil equivalent per day, in line with guidance.

----------

ValiRx PLC - clinical stage drug development company - Pretax loss in 2020 narrows to GBP1.5 million from GBP2.7 million. Other operating income reduced to GBP11,077 from GBP146,517, but research and development costs decline 77% to GBP230,115 from GBP984,457. "We are looking forward to 2021 and are confident in the outlook for ValiRx," Chief Executive Officer Suzy Dilly says.

----------

Inspiration Healthcare Group PLC - West Sussex-based medical technology company - Revenue more than doubles to GBP37.0 million in financial year that ended January 31 from GBP17.8 million. Pretax profit jumps to GBP3.1 million from GBP1.1 million. Declares 0.6p worth of dividends for 2020, having made no payouts for 2019. "Our current financial year has started well and in line with our expectations with a strong order book across the group. However, this year will not be without bumps in the road as we expect there will be issues with Covid-19 in the world economy for a while," Inspiration says. "At this early stage in our financial year, with the vast majority of our products serving a critical area we remain confident that we will continue with our plans for significant future growth and our expectations remain unchanged."

----------

Baillie Gifford China Growth Trust PLC - aims for long-term capital growth by investing in Chinese companies - Net asset value at January 31 year-end up 36% year-on-year to 492.66 pence per share from 363.49p. Net asset value total return was 38%, compared to 22% from benchmark. Dividend maintained at 7.15p per share.

----------

Fidelity Asian Values PLC - provides equity exposure to Asian businesses considered mispriced - Net asset value per share at January 31, end of first half, up 20% to 437.08 pence, from 364.39p at the end of July. "In Asia, there was an expectation that investors would rotate out of growth stocks and into value names in the last quarter of 2020 in the hope that value would benefit from an economic recovery. However, this trend has not played out to the extent we expected and stock selection was the key driver of the company's relative performance," Fidelity says.

----------

Dunedin Income Growth Investment Trust PLC - Edinburgh-based UK and overseas companies investor - Net asset value total return of negative 0.3% in financial year ended January 31 topped by benchmark's 22% hike. Net asset value per share falls 4.6% annually to 302.56p from 317.04p. Ups payout by 0.8% to 12.80p per share from 12.70p.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.